Who owns ACRIVON THERAPEUTICS INC?
- Ticker: ACRV
- CUSIP Number: 004890109
Tip: Access positions for across all investors
Analyze quarterly positions in Acrivon Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Acrivon Therapeutics stock
Who bought or sold ACRIVON THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 8.3M | $15M | 0% | Sep 2025 |
|
| Sands Capital Ventures | 2.1M | $3.8M | 0% | Sep 2025 |
|
| Citadel Advisors | 1.5M | $2.8M | -19% | Sep 2025 |
|
| Wellington Management Company | 888k | $1.6M | 0% | Sep 2025 |
|
| UBS Group | 683k | $1.2M | 150058% | Sep 2025 |
|
| Vanguard Group | 626k | $1.1M | 6% | Sep 2025 |
|
| Renaissance Technologies | 623k | $1.1M | 22% | Sep 2025 |
|
| Acorn Capital Advisors | 405k | $734k | 0% | Sep 2025 |
|
| BlackRock | 331k | $599k | -19% | Sep 2025 |
|
| Two Sigma Investments | 319k | $578k | 76% | Sep 2025 |
|
| Jane Street | 289k | $524k | -7% | Sep 2025 |
|
| Geode Capital Management | 192k | $348k | 17% | Sep 2025 |
|
| Millennium Management | 185k | $335k | -37% | Sep 2025 |
|
| Marshall Wace | 150k | $271k | -17% | Sep 2025 |
|
| Two Sigma Advisers | 137k | $247k | 319% | Sep 2025 |
|
| Squarepoint Ops | 104k | $189k | -32% | Sep 2025 |
|
| Acadian Asset Management | 92k | $165k | 100% | Sep 2025 |
|
| State Street Corporation | 67k | $122k | 0% | Sep 2025 |
|
| Morgan Stanley | 63k | $75k | 100% | Jun 2025 |
|
| Algert Coldiron Investors | 45k | $81k | 100% | Sep 2025 |
|
| Northern Trust | 42k | $76k | -10% | Sep 2025 |
|
| XTX Topco | 36k | $65k | -66% | Sep 2025 |
|
| Bridgeway Capital Management | 23k | $41k | 0% | Sep 2025 |
|
| Baker Bros. Advisors | 23k | $41k | 0% | Sep 2025 |
|
| Barclays | 20k | $36k | -5% | Sep 2025 |
|
| Colony | 20k | $988k | 100% | Sep 2025 |
|
| Goldman Sachs Group | 20k | $36k | -66% | Sep 2025 |
|
| Dimensional Fund Advisors | 20k | $35k | -12% | Sep 2025 |
|
| AAFCPAs Wealth Management | 11k | $19k | 100% | Sep 2025 |
|
| Tower Research Capital | 8.7k | $16k | -1% | Sep 2025 |
|
| FMR | 8.6k | $16k | -12% | Sep 2025 |
|
| China Universal Asset Management | 5.5k | $10k | -12% | Sep 2025 |
|
| Federated Investors | 2.4k | $4.4k | 5% | Sep 2025 |
|
| Jpmorgan Chase & Co | 1.7k | $3.2k | -79% | Sep 2025 |
|
| Mirae Asset Global Investments | 1.2k | $2.2k | 0% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 1.2k | $2.2k | 20% | Sep 2025 |
|
| Royal Bank of Canada | 948.00 | $0 | 2958% | Sep 2025 |
|
| Gf Fund Management | 650.00 | $1.2k | -16% | Sep 2025 |
|
| NISA Investment Advisors | 584.00 | $1.1k | 0% | Sep 2025 |
|
| Redwood Park Advisors | 500.00 | $905.000000 | 0% | Sep 2025 |
|
| Russell Investments | 481.00 | $870.994800 | 0% | Sep 2025 |
|
| Federation des caisses Desjardins du Quebec | 400.00 | $724.000000 | 0% | Sep 2025 |
|
| EverSource Wealth Advisors | 373.00 | $675.018100 | 100% | Sep 2025 |
|
| CWM | 127.00 | $0 | -84% | Sep 2025 |
|
| SBI Securities | 74.00 | $133.999200 | 0% | Sep 2025 |
|
Who sold out of Acrivon Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Jacobs Levy Equity Management | Jun 2025 | 382k | $455k |
| Hrt Financial | Jun 2025 | 146k | $173k |
| Charles Schwab Investment Management | Jun 2025 | 64k | $76k |
| Susquehanna International | Jun 2025 | 44k | $52k |
| AQR Capital Management | Jun 2025 | 22k | $27k |
| SG Americas Securities | Jun 2025 | 15k | $18k |
| Qube Research & Technologies | Jun 2025 | 13k | $15k |
| Ground Swell Capital | Jun 2025 | 12k | $15k |
| True Wealth Design | Jun 2025 | 176.00 | $210.003200 |
| Wells Fargo & Company | Jun 2025 | 141.00 | $168.001500 |